Half-Century of Cancer Biomarkers:: Lessons from the Past and Projections for the Future

Panagiota Filippou; Eleftherios P. Diamandis

doi:10.1373/jalm.2016.021824

Half-Century of Cancer Biomarkers: Lessons from the Past and Projections for the Future

Panagiota Filippou
, Eleftherios P. Diamandis

Centre for Biodiscovery

Research output: Contribution to journal › Article › peer-review

Abstract

A handful of cancer biomarkers are used widely in clinical practice, mainly for aiding in diagnosis and for monitoring therapy. These biomarkers include α-fetoprotein (AFP),4 carcinoembryonic antigen (CEA), prostate-specific antigen, and the carbohydrate antigens CA125, CA19.9, and CA15.3. Other, more specialized cancer biomarkers are used less frequently. Molecular/genomic markers will not be discussed here.

Original language	English
Pages (from-to)	288
Number of pages	290
Journal	Journal of Applied Laboratory Medicine
Volume	2
Issue number	2
DOIs	https://doi.org/10.1373/jalm.2016.021824
Publication status	Published - 15 Oct 2019

Access to Document

10.1373/jalm.2016.021824Licence: CC BY-NC-ND

Cite this

@article{a1f3862964044fd492850d0c05944f0b,

title = "Half-Century of Cancer Biomarkers:: Lessons from the Past and Projections for the Future",

abstract = "A handful of cancer biomarkers are used widely in clinical practice, mainly for aiding in diagnosis and for monitoring therapy. These biomarkers include α-fetoprotein (AFP),4 carcinoembryonic antigen (CEA), prostate-specific antigen, and the carbohydrate antigens CA125, CA19.9, and CA15.3. Other, more specialized cancer biomarkers are used less frequently. Molecular/genomic markers will not be discussed here.",

author = "Panagiota Filippou and Diamandis, \{Eleftherios P.\}",

year = "2019",

month = oct,

day = "15",

doi = "10.1373/jalm.2016.021824",

language = "English",

volume = "2",

pages = "288",

journal = "Journal of Applied Laboratory Medicine",

issn = "2475-7241",

publisher = "Oxford University Press",

number = "2",

}

TY - JOUR

T1 - Half-Century of Cancer Biomarkers:

T2 - Lessons from the Past and Projections for the Future

AU - Filippou, Panagiota

AU - Diamandis, Eleftherios P.

PY - 2019/10/15

Y1 - 2019/10/15

N2 - A handful of cancer biomarkers are used widely in clinical practice, mainly for aiding in diagnosis and for monitoring therapy. These biomarkers include α-fetoprotein (AFP),4 carcinoembryonic antigen (CEA), prostate-specific antigen, and the carbohydrate antigens CA125, CA19.9, and CA15.3. Other, more specialized cancer biomarkers are used less frequently. Molecular/genomic markers will not be discussed here.

AB - A handful of cancer biomarkers are used widely in clinical practice, mainly for aiding in diagnosis and for monitoring therapy. These biomarkers include α-fetoprotein (AFP),4 carcinoembryonic antigen (CEA), prostate-specific antigen, and the carbohydrate antigens CA125, CA19.9, and CA15.3. Other, more specialized cancer biomarkers are used less frequently. Molecular/genomic markers will not be discussed here.

U2 - 10.1373/jalm.2016.021824

DO - 10.1373/jalm.2016.021824

M3 - Article

SN - 2475-7241

VL - 2

SP - 288

JO - Journal of Applied Laboratory Medicine

JF - Journal of Applied Laboratory Medicine

IS - 2

ER -

Half-Century of Cancer Biomarkers: Lessons from the Past and Projections for the Future

Abstract

Access to Document

Fingerprint

Cite this